Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 697 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Lexeo Therapeutics, Inc. Common Stock
Market Cap
$264.23M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$265.12M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
-5482.65%
5Y Avg
-3802.53%
Market Cap
$262.97M
Net Profit Margin
-6388.20%
TTM Avg
0.00%
3Y Avg
-1230.00%
5Y Avg
-820.00%
Market Cap
$268.17M
Net Profit Margin
-43.70%
TTM Avg
-35.13%
3Y Avg
-15.36%
5Y Avg
-13.33%
Market Cap
$268.87M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$269.13M
Net Profit Margin
-10994.73%
TTM Avg
-520.92%
3Y Avg
-360.66%
5Y Avg
-288.77%
Market Cap
$258.32M
Net Profit Margin
-3.14%
TTM Avg
-28.33%
3Y Avg
-34.54%
5Y Avg
-25.62%
Market Cap
$257.49M
Net Profit Margin
-249.94%
TTM Avg
-1079.05%
3Y Avg
-1080.63%
5Y Avg
-787.30%
Market Cap
$250.79M
Net Profit Margin
-8.78%
TTM Avg
-964.82%
3Y Avg
-2640.79%
5Y Avg
-1760.53%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexeo Therapeutics, Inc. Common Stock (LXEO) | $264.23M | 0.00% | 0.00% | 0.00% | N/A |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $265.12M | 0.00% | 0.00% | -5482.65% | -3802.53% |
| Palisade Bio, Inc. (PALI)vs › | $262.97M | -6388.20% | 0.00% | -1230.00% | -820.00% |
| OraSure Technologies, Inc. (OSUR)vs › | $268.17M | -43.70% | -35.13% | -15.36% | -13.33% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $268.87M | 0.00% | 0.00% | 0.00% | 0.00% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $269.13M | -10994.73% | -520.92% | -360.66% | -288.77% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.32M | -3.14% | -28.33% | -34.54% | -25.62% |
| AC Immune S.A. (ACIU)vs › | $257.49M | -249.94% | -1079.05% | -1080.63% | -787.30% |
| Century Therapeutics, Inc. (IPSC)vs › | $250.79M | -8.78% | -964.82% | -2640.79% | -1760.53% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $276.08M | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | -3211.86% |
| 2022-06-30 | -40927.03% |
| 2022-03-31 | -14613.48% |
